Platelet and monocyte activity markers and mediators of XXXX in @entity661 .

@entity1 @entity32 @entity650 @entity2936 @entity6977 @entity11603 @entity2842 @entity8729 @entity661 @entity583
@entity1 with @entity661 ( @entity661 ) often present with symptoms similar to those of @entity583 ( @entity583 ). We analyzed blood concentrations of mediators of @entity32 and platelet- and monocyte-activity markers in @entity1 with @entity661 and @entity583 for significant differences. Clinical data of @entity1 with @entity661 (n = 16) and acute @entity583 (n = 16) were obtained. Serial blood samples were taken at the time of hospital admission (t(0)), after 2-4 days (t(1)) and after 4-7 weeks (t(2)), respectively. Plasma concentrations of @entity650 , @entity6977 , soluble @entity2936 ligand (sCD40L), and @entity2842 ( @entity2842 ) were determined with an ELISA. Tissue factor binding on monocytes, platelet-activation marker @entity8729 , platelet @entity11603 ( @entity11603 ), and platelet-monocyte aggregates were measured using flow cytometry. Expression of @entity8729 on platelets and @entity650 plasma levels were significantly lower in @entity1 with @entity661 compared to @entity583 at the time of hospital admission. @entity6977 plasma levels were significantly elevated in @entity1 with @entity661 compared to @entity1 with @entity583 at 2-4 days after hospital admission. No significant differences were observed concerning sCD40L and @entity2842 plasma levels, tissue factor binding on monocytes, @entity11603 expression on platelets, and platelet-monocyte aggregates at any point in time. Our results indicate that inflammatory mediators and platelet-activity markers contribute to the differences in the pathogenesis of @entity583 and @entity661 .
